Shares of Eli Lilly (NYSE: LLY) have more than doubled over the past 12 months, but Wall Street analysts who watch the big pharma company think it has more fuel in the tank.

For example, J.P. Morgan recently raised its price target on Eli Lilly to $1,000 from $900, citing sales of Mounjaro and Zepbound that keep soaring.

Eli Lilly will most likely report second-quarter earnings during the second week of August. expects compelling results that could push the pharmaceutical stock up to $1,025 over the next 12 months.

Continue reading

Source Fool.com